Last quarter (Q4 2023), Aadi Bioscience's total revenue was $6.33M, an increase of 21.03% from the same quarter last year. In Q4, Aadi Bioscience's net income was $-16.27M. See Aadi Bioscience’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 24.35M	$ 24.35M	$ 15.22M	$ 1.12M	$ 14.00M
Cost of Revenue	$ 2.81M	$ 2.81M	$ 1.33M	$ -578.00K	-
Gross Profit	$ 21.55M	$ 21.55M	$ 13.88M	$ 1.12M	-
Operating Expense	$ 93.48M	$ 93.48M	$ 72.84M	$ 38.18M	$ 16.55M
Operating Income	$ -71.93M	$ -71.93M	$ -62.68M	$ -37.06M	$ -2.55M
Net Non Operating Interest Income Expense	$ 6.17M	$ 6.17M	$ 2.17M	$ -652.00K	$ -774.00K
Other Income Expense	$ -7.40M	-	$ 3.72M	$ 72.38M	$ -153.00K
Pretax Income	$ -65.77M	$ -65.77M	$ -60.51M	$ -110.09M	$ -3.48M
Tax Provision	-	-	-	$ 2.00K	$ 2.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -65.77M	$ -65.77M	$ -60.51M	$ -110.74M	$ -4.46M
Basic EPS	$ -2.44	$ -2.44	$ -2.69	$ -12.41	$ -0.21
Diluted EPS	$ -2.44	$ -2.44	$ -2.69	$ -12.41	$ -0.21
Basic Average Shares	$ 107.67M	$ 26.92M	$ 22.51M	$ 8.92M	$ 20.84M
Diluted Average Shares	$ 107.67M	$ 26.92M	$ 22.51M	$ 8.92M	$ 20.84M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 96.29M	$ 96.29M	$ 71.50M	$ 111.76M	$ 16.55M
Net Income From Continuing And Discontinued Operation	$ -65.77M	$ -65.77M	$ -60.51M	$ -110.09M	$ -3.48M
Normalized Income	$ -43.63M	$ -51.95M	-	-	$ -3.48M
Interest Expense	-	-	-	-	$ 815.00K
EBIT	$ -65.53M	$ -65.53M	$ -60.28M	$ -109.42M	$ -2.66M
EBITDA	$ -68.50M	$ -68.50M	$ -61.34M	$ -109.32M	$ -2.65M

Currency in USD

Aadi Bioscience Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing